<DOC>
	<DOCNO>NCT01447550</DOCNO>
	<brief_summary>This study assess effectiveness safety bosentan administer thromboangiitis obliterans ( Buerger 's disease ) patient . A clinical pilot study design , include patient ulcer and/or pain rest treat bosentan p.o dose 62,5 mg twice daily first month , thereafter uptitrated 125 mg twice daily . Study endpoints clinical improvement rate , major minor amputation rate , hemodynamic change , change endothelial function angiographic change . 12 patient include current smoker . With bosentan treatment , new ischemic lesion observe one patient . Overall , clinical improvement observe 12 13 extremity ( 92 % ) . Only two 13 extremity underwent amputation bosentan treatment . As assessed digital arteriography subtraction angio-magnetic resonance image increase distal flow observe 10 12 patient . All patient experience statistically significant improvement BAFMD value ( means:1.8 baseline ; 6.6 end treatment ; 12.7 three month end treatment ; p &lt; 0.01 ) . In conclusion : Bosentan treatment may result improvement clinical , angiographic , hemodynamic endothelial function outcome . Bosentan deserve investigation management TAO patient .</brief_summary>
	<brief_title>Treatment Thromboangiitis Obliterans ( Buerguer 's Disease ) With Bosentan</brief_title>
	<detailed_description />
	<mesh_term>Thromboangiitis Obliterans</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Critical ischemia extremity , cause pain rest nonhealing ischemic ulcer , present least four week evidence improvement response conventional treatment . Being candidate surgical endovascular revascularisation extremity study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Bosentan</keyword>
	<keyword>Buerguer disease</keyword>
</DOC>